Savara: The Rare Disease Funnel Is Becoming A Commercial Asset (NASDAQ:SVRA)
· seekingalpha.com
Savara is transitioning from a single-asset biotech to a rare disease commercial infrastructure. Click here to read more on SVRA stock.
I'm very optimistic about Savara ( SVRA ) because investors are continuing to evaluate the company as a single-asset biotech rather than a developing rare disea...